US Patent 7223725 Exendin agonist compounds
Patent 7223725 was granted and assigned to Amylin Pharmaceuticals on May, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Kathryn Susan Prickett0
Nigel Robert Arnold Beeley0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+240 characters)
Article
Patent abstract
The present invention relates to novel exendin agonist compounds useful in treatment of Type I and II diabetes, and useful in lowering plasma glucose levels, reducing body weight, and delaying and/or slowing gastric emptying.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07223725 Exendin agonist compounds US Patent 7223725 Exendin agonist compounds
Infobox
Patent Number
072237250
Patent Number
72237250
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072237250
Date of Patent
May 29, 2007
0Patent Application Number
095545330
Date Filed
November 13, 1998
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07223725 Exendin agonist compounds
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07223725
Date of patent
May 29, 2007
Patent application number
09554533
Date Filed
November 13, 1998
Patent primary examiner
Find more entities like US Patent 7223725 Exendin agonist compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
